Reading on the Ascenta website, it looks like we have a horse race. Similar intent, level of,progress in clinical trials, and lack of toxicity. One has to expect with a prize of this magnitude that more than one entity will be seeking results. I would be pleased to see Kevertin in the NYT, but in the long run what matters is clinical success.

Being first mover in this P53 issue will be critical...and is to expected that Cellceutix scientists are not the only ones working at it, even at the very same cancer centers where we are in trials. Excited as we can be about Cellceutix, it is critica as an investor not to allow confirmation bias to cloud honest assessment of the competitive landscape.

If anyone with a science background can provide any further comparison, opinion is definitely welcome on any marked advantages or disadvantages of Kevertin vs. Ascentas compound.

Thanks! ...Just trying to keep it real